The Community Guide

- gsearch

Search Results

Narrow Results:

2021 1
2018 1
2017 2
2013 2
2011 2
2010 1
2006 2
2003 3
1993 1

Journal Article 14
Journal Issue 1

Letter 1
Practice Guideline 1

1 - 15 of 15 Results

Refine Results

Refine Results:

Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis

CITE Title : Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis Personal Author(s) : Marks, Suzanne M.;Mase, Sundari R.;Morris, Sapna Bamrah; Published Date : Jun 15 2017 Source : Clin Infect Dis. 64(12):1670-1677 URL : https://stacks.cdc.gov/view/cdc/47333 Marks, Suzanne M. et al. (2017). Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis. 64(12). Marks, Suzanne M. and Mase, Sundari R. and Morris, Sapna Bamrah "Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis" 64, no. 12 (2017) Marks, Suzanne M. et al. "Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis" vol. 64, no. 12, 2017 Export RIS Citation Information.

:

Marks, Suzanne M. ;

Mase, Sundari R.

Jun 15 2017 | Clin Infect Dis. 64(12):1670-1677

:

BackgroundEvidence-based recommendations for treating persons having presumed latent tuberculosis (LTBI) after contact to infectious multidrug-resista...
When Tuberculosis Comes Back: Who Develops Recurrent Tuberculosis in California?

CITE Title : When Tuberculosis Comes Back: Who Develops Recurrent Tuberculosis in California? Personal Author(s) : Pascopella, Lisa;DeRiemer, Kathryn;Watt, James P.;Flood, Jennifer M.; Published Date : Nov 01 2011 Source : PLoS One. 2011; 6(11). URL : https://stacks.cdc.gov/view/cdc/22795 Pascopella, Lisa et al. (2011). When Tuberculosis Comes Back: Who Develops Recurrent Tuberculosis in California?. 6(11). Pascopella, Lisa et al. "When Tuberculosis Comes Back: Who Develops Recurrent Tuberculosis in California?" 6, no. 11 (2011) Pascopella, Lisa et al. "When Tuberculosis Comes Back: Who Develops Recurrent Tuberculosis in California?" vol. 6, no. 11, 2011 Export RIS Citation Information.

:

Pascopella, Lisa ;

DeRiemer, Kathryn

Nov 01 2011 | PLoS One. 2011; 6(11).

:

BackgroundRecurrent tuberculosis suggests potentially modifiable gaps in tuberculosis treatment and control activities. The frequency of late recurren...
Molecular Detection of Mutations Associated with First- and Second-Line Drug Resistance Compared with Conventional Drug Susceptibility Testing of Mycobacterium tuberculosis

CITE Title : Molecular Detection of Mutations Associated with First- and Second-Line Drug Resistance Compared with Conventional Drug Susceptibility Testing of Mycobacterium tuberculosis Personal Author(s) : Campbell, Patricia J.;Morlock, Glenn P.;Sikes, R. David;Dalton, Tracy L.;Metchock, Beverly;Starks, Angela M.;Hooks, Delaina P.;Cowan, Lauren S.;Plikaytis, Bonnie B.;Posey, James E.; Published Date : May 2011 Source : Antimicrobial Agents and Chemotherapy. 2011; 55(5):2032-2041. URL : https://stacks.cdc.gov/view/cdc/4393 Campbell, Patricia J. et al. (2011). Molecular Detection of Mutations Associated with First- and Second-Line Drug Resistance Compared with Conventional Drug Susceptibility Testing of Mycobacterium tuberculosis. Campbell, Patricia J. et al. "Molecular Detection of Mutations Associated with First- and Second-Line Drug Resistance Compared with Conventional Drug Susceptibility Testing of Mycobacterium tuberculosis" (2011) Campbell, Patricia J. et al. "Molecular Detection of Mutations Associated with First- and Second-Line Drug Resistance Compared with Conventional Drug Susceptibility Testing of Mycobacterium tuberculosis" , 2011 Export RIS Citation Information.

:

Campbell, Patricia J. ;

Morlock, Glenn P.

May 2011 | Antimicrobial Agents and Chemotherapy. 2011; 55(5):2032-2041.

:

The emergence of multi- and extensively drug-resistant tuberculosis is a significant impediment to the control of this disease because treatment becom...
Multidrug-resistant Tuberculosis in Military Recruits

CITE Title : Multidrug-resistant Tuberculosis in Military Recruits Personal Author(s) : Freier, Grace;Wright, Allen;Nelson, Gregory;Brenner, Eric;Mase, Sundari;Tasker, Sybil;Matthews, Karen L.;Bohnker, Bruce K.; Published Date : May 2006 Source : Emerg Infect Dis. 12(5):760-762. URL : https://stacks.cdc.gov/view/cdc/15959 Freier, Grace et al. (2006). Multidrug-resistant Tuberculosis in Military Recruits. 12(5). Freier, Grace et al. "Multidrug-resistant Tuberculosis in Military Recruits" 12, no. 5 (2006) Freier, Grace et al. "Multidrug-resistant Tuberculosis in Military Recruits" vol. 12, no. 5, 2006 Export RIS Citation Information.

:

Freier, Grace ;

Wright, Allen

May 2006 | Emerg Infect Dis. 12(5):760-762.

:

We conducted a tuberculosis contact investigation for a female military recruit with an unreported history of multidrug-resistant tuberculosis (MDRTB)...
Multidrug-resistant Mycobacterium tuberculosis in HIV-Infected Persons, Peru

CITE Title : Multidrug-resistant Mycobacterium tuberculosis in HIV-Infected Persons, Peru Personal Author(s) : Campos, Pablo E.;Suarez, Pedro G.;Sanchez, Jorge;Zavala, David;Arevalo, Jorge;Ticona, Eduardo;Nolan, Charles M.;Hooton, Thomas M.;Holmes, King K.; Published Date : Dec 2003 Source : Emerg Infect Dis. 9(12):1571-1578. URL : https://stacks.cdc.gov/view/cdc/14173 Campos, Pablo E. et al. (2003). Multidrug-resistant Mycobacterium tuberculosis in HIV-Infected Persons, Peru. 9(12). Campos, Pablo E. et al. "Multidrug-resistant Mycobacterium tuberculosis in HIV-Infected Persons, Peru" 9, no. 12 (2003) Campos, Pablo E. et al. "Multidrug-resistant Mycobacterium tuberculosis in HIV-Infected Persons, Peru" vol. 9, no. 12, 2003 Export RIS Citation Information.

:

Campos, Pablo E. ;

Suarez, Pedro G.

Dec 2003 | Emerg Infect Dis. 9(12):1571-1578.

:

During 1999 to 2000, we identified HIV-infected persons with new episodes of tuberculosis (TB) at 10 hospitals in Lima, Peru, and a random sample of o...
Mycobacterium bovis Isolates with M. tuberculosis Specific Characteristics

CITE Title : Mycobacterium bovis Isolates with M. tuberculosis Specific Characteristics Personal Author(s) : Kubica, Tanja;Agzamova, Rimma;Wright, Abigail;Rakishev, Galimzhan;Rüsch-Gerdes, Sabine;Niemann, Stefan; Published Date : May 2006 Source : Emerg Infect Dis. 12(5):763-765. URL : https://stacks.cdc.gov/view/cdc/15856 Kubica, Tanja et al. (2006). Mycobacterium bovis Isolates with M. tuberculosis Specific Characteristics. 12(5). Kubica, Tanja et al. "Mycobacterium bovis Isolates with M. tuberculosis Specific Characteristics" 12, no. 5 (2006) Kubica, Tanja et al. "Mycobacterium bovis Isolates with M. tuberculosis Specific Characteristics" vol. 12, no. 5, 2006 Export RIS Citation Information.

:

Kubica, Tanja ;

Agzamova, Rimma

May 2006 | Emerg Infect Dis. 12(5):763-765.

:

Our study is the first report of exceptional Mycobacterium bovis strains that have some characteristics of M. tuberculosis. The strains were isolated ...
Emergence of Increased Resistance and Extensively Drug-Resistant Tuberculosis Despite Treatment Adherence, South Africa

CITE Title : Emergence of Increased Resistance and Extensively Drug-Resistant Tuberculosis Despite Treatment Adherence, South Africa Personal Author(s) : Calver, Alistair D.;Falmer, Alecia A.;Murray, Megan;Strauss, Odelia J.;Streicher, Elizabeth M.;Hanekom, Madelene;Liversage, Thelma;Masibi, Mothusi;van Helden, Paul D.;Warren, Robin M.;Victor, Thomas C.; Published Date : Feb 2010 Source : Emerg Infect Dis. 16(2):264-271. URL : https://stacks.cdc.gov/view/cdc/18008 Calver, Alistair D. et al. (2010). Emergence of Increased Resistance and Extensively Drug-Resistant Tuberculosis Despite Treatment Adherence, South Africa. 16(2). Calver, Alistair D. et al. "Emergence of Increased Resistance and Extensively Drug-Resistant Tuberculosis Despite Treatment Adherence, South Africa" 16, no. 2 (2010) Calver, Alistair D. et al. "Emergence of Increased Resistance and Extensively Drug-Resistant Tuberculosis Despite Treatment Adherence, South Africa" vol. 16, no. 2, 2010 Export RIS Citation Information.

:

Calver, Alistair D. ;

Falmer, Alecia A.

Feb 2010 | Emerg Infect Dis. 16(2):264-271.

:

We investigated the emergence and evolution of drug-resistant tuberculosis (TB) in an HIV co-infected population at a South African gold mine with a w...
Treatment Outcomes for Extensively Drug-Resistant Tuberculosis and HIV Co-infection

CITE Title : Treatment Outcomes for Extensively Drug-Resistant Tuberculosis and HIV Co-infection Personal Author(s) : O’Donnell, Max R.;Padayatchi, Nesri;Kvasnovsky, Charlotte;Werner, Lise;Master, Iqbal;Horsburgh, C. Robert; Published Date : Mar 2013 Source : Emerg Infect Dis. 19(3):416-424. URL : https://stacks.cdc.gov/view/cdc/18935 O’Donnell, Max R. et al. (2013). Treatment Outcomes for Extensively Drug-Resistant Tuberculosis and HIV Co-infection. 19(3). O’Donnell, Max R. et al. "Treatment Outcomes for Extensively Drug-Resistant Tuberculosis and HIV Co-infection" 19, no. 3 (2013) O’Donnell, Max R. et al. "Treatment Outcomes for Extensively Drug-Resistant Tuberculosis and HIV Co-infection" vol. 19, no. 3, 2013 Export RIS Citation Information.

:

O’Donnell, Max R. ;

Padayatchi, Nesri

Mar 2013 | Emerg Infect Dis. 19(3):416-424.

:

High mortality rates have been reported for patients co-infected with extensively drug-resistant tuberculosis (XDR-TB) and HIV, but treatment outcomes...
Optimizing pyrazinamide for the treatment of tuberculosis

CITE Title : Optimizing pyrazinamide for the treatment of tuberculosis Personal Author(s) : Zhang, Nan;Savic, Radojka M.;Boeree, Martin J.;Peloquin, Charles;Weiner, Marc;Heinrich, Norbert;Bliven-Sizemore, Erin;Phillips, Patrick PJ;Hoelscher, Michael;Whitworth, William;Morlock, Glenn;Posey, James;Stout, Jason E.;Kenzie, William Mac;Aarnoutse, Robert;Dooley, Kelly E.; Corporate Authors(s) : Tuberculosis Trials Consortium (TBTC) and Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA) Networks Published Date : 7 2021;7-2021; Source : Eur Respir J. 58(1) URL : https://stacks.cdc.gov/view/cdc/109118 Zhang, Nan et al. (2021). Optimizing pyrazinamide for the treatment of tuberculosis. 58(1). Zhang, Nan et al. "Optimizing pyrazinamide for the treatment of tuberculosis" 58, no. 1 (2021) Zhang, Nan et al. "Optimizing pyrazinamide for the treatment of tuberculosis" vol. 58, no. 1, 2021 Export RIS Citation Information.

:

Zhang, Nan ;

Savic, Radojka M.

7 2021 | Eur Respir J. 58(1)

:

Pyrazinamide is a potent sterilising agent that shortens the treatment duration needed to cure tuberculosis. It is synergistic with novel and existing...
pncA Gene Mutations Associated with Pyrazinamide Resistance in Drug-Resistant Tuberculosis, South Africa and Georgia

CITE Title : pncA Gene Mutations Associated with Pyrazinamide Resistance in Drug-Resistant Tuberculosis, South Africa and Georgia Personal Author(s) : Allana, Salim;Shashkina, Elena;Mathema, Barun;Bablishvili, Nino;Tukvadze, Nestani;Shah, N. Sarita;Kempker, Russell R.;Blumberg, Henry M.;Moodley, Pravi;Mlisana, Koleka;Brust, James C.M.;Gandhi, Neel R.; Published Date : Mar 2017 Source : Emerg Infect Dis. 23(3):491-495. URL : https://stacks.cdc.gov/view/cdc/44927 Allana, Salim et al. (2017). pncA Gene Mutations Associated with Pyrazinamide Resistance in Drug-Resistant Tuberculosis, South Africa and Georgia. 23(3). Allana, Salim et al. "pncA Gene Mutations Associated with Pyrazinamide Resistance in Drug-Resistant Tuberculosis, South Africa and Georgia" 23, no. 3 (2017) Allana, Salim et al. "pncA Gene Mutations Associated with Pyrazinamide Resistance in Drug-Resistant Tuberculosis, South Africa and Georgia" vol. 23, no. 3, 2017 Export RIS Citation Information.

:

Allana, Salim ;

Shashkina, Elena

Mar 2017 | Emerg Infect Dis. 23(3):491-495.

:

Although pyrazinamide is commonly used for tuberculosis treatment, drug-susceptibility testing is not routinely available. We found polymorphisms in t...
Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009

CITE Title : Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009 Personal Author(s) : Kurbatova, Ekaterina V.;Cavanaugh, Joseph S.;Dalton, Tracy;Click, Eleanor;Cegielski, J. Peter; Published Date : 10 2013;10-2013; Source : Clin Infect Dis. 57(8):1081-1093 URL : https://stacks.cdc.gov/view/cdc/34431 Kurbatova, Ekaterina V. et al. (2013). Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009. 57(8). Kurbatova, Ekaterina V. et al. "Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009" 57, no. 8 (2013) Kurbatova, Ekaterina V. et al. "Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009" vol. 57, no. 8, 2013 Export RIS Citation Information.

:

Kurbatova, Ekaterina V. ;

Cavanaugh, Joseph S.

10 2013 | Clin Infect Dis. 57(8):1081-1093

:

IntroductionPyrazinamide (PZA) is essential in tuberculosis (TB) treatment. We describe the prevalence, trends and predictors of PZA resistance in Myc...
Drug-Resistant Mycobacterium tuberculosis among New Tuberculosis Patients, Yangon, Myanmar

CITE Title : Drug-Resistant Mycobacterium tuberculosis among New Tuberculosis Patients, Yangon, Myanmar Personal Author(s) : Phyu, Sabai;Ti, Ti;Jureen, Roland;Hmun, Thandar;Myint, Hlaing;Htun, Aye;Grewal, Harleen M.S.;Bjorvatn, Bjarne; Published Date : Feb 2003 Source : Emerg Infect Dis. 9(2):274-276 URL : https://stacks.cdc.gov/view/cdc/13958 Phyu, Sabai et al. (2003). Drug-Resistant Mycobacterium tuberculosis among New Tuberculosis Patients, Yangon, Myanmar. 9(2). Phyu, Sabai et al. "Drug-Resistant Mycobacterium tuberculosis among New Tuberculosis Patients, Yangon, Myanmar" 9, no. 2 (2003) Phyu, Sabai et al. "Drug-Resistant Mycobacterium tuberculosis among New Tuberculosis Patients, Yangon, Myanmar" vol. 9, no. 2, 2003 Export RIS Citation Information.

:

Phyu, Sabai ;

Ti, Ti

Feb 2003 | Emerg Infect Dis. 9(2):274-276

No Description
Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis

CITE Title : Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis Personal Author(s) : Fregonese, Federica;Ahuja, Shama D;Akkerman, Onno W;Arakaki-Sanchez, Denise;Ayakaka, Irene;Baghaei, Parvaneh;Bang, Didi;Bastos, Mayara;Benedetti, Andrea;Bonnet, Maryline;Cattamanchi, Adithya;Cegielski, Peter;Chien, Jung-Yien;Cox, Helen;Dedicoat, Martin;Erkens, Connie;Escalante, Patricio;Falzon, Dennis;Garcia-Prats, Anthony J;Gegia, Medea;Gillespie, Stephen H;Glynn, Judith R;Goldberg, Stefan;Griffith, David;Jacobson, Karen R;Johnston, James C;Jones-López, Edward C;Khan, Awal;Koh, Won-Jung;Kritski, Afranio;Lan, Zhi Yi;Lee, Jae Ho;Li, Pei Zhi;Maciel, Ethel L;Galliez, Rafael Mello;Merle, Corinne S C;Munang, Melinda;Narendran, Gopalan;Nguyen, Viet Nhung;Nunn, Andrew;Ohkado, Akihiro;Park, Jong Sun;Phillips, Patrick P J;Ponnuraja, Chinnaiyan;Reves, Randall;Romanowski, Kamila;Seung, Kwonjune;Schaaf, H Simon;Skrahina, Alena;van Soolingen, Dick;Tabarsi, Payam;Trajman, Anete;Trieu, Lisa;Banurekha, Velayutham V;Viiklepp, Piret;Wang, Jann-Yuan;Yoshiyama, Takashi;Menzies, Dick; Published Date : 4 2018;4-2018; Source : Lancet Respir Med. 6(4):265-275 URL : https://stacks.cdc.gov/view/cdc/116493 Fregonese, Federica et al. (2018). Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. 6(4). Fregonese, Federica et al. "Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis" 6, no. 4 (2018) Fregonese, Federica et al. "Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis" vol. 6, no. 4, 2018 Export RIS Citation Information.

:

Fregonese, Federica ;

Ahuja, Shama D

4 2018 | Lancet Respir Med. 6(4):265-275

:

BackgroundIsoniazid-resistant, rifampicin-susceptible (INH-R) tuberculosis is the most common form of drug resistance, and is associated with failure,...
Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection---United States, 2003

CITE Title : Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection---United States, 2003 Corporate Authors(s) : Centers for Disease Control and Prevention (U.S.);American Thoracic Society.; Published Date : August 8, 2003 Pages in Document : 5 pdf pages Series : Weekly Report: Morbidity and Mortality Weekly Report (MMWR) Source : MMWR. Morbidity and mortality weekly report. 2003; 52(31):735-9. URL : https://stacks.cdc.gov/view/cdc/7296 Journal Title : Morbidity and Mortality Weekly Report (MMWR) Centers for Disease Control and Prevention (U.S.) (2003). Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection---United States, 2003. 52(31). Centers for Disease Control and Prevention (U.S.) "Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection---United States, 2003" 52, no. 31 (2003) Centers for Disease Control and Prevention (U.S.) "Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection---United States, 2003" vol. 52, no. 31, 2003 Export RIS Citation Information.

:

Centers for Disease Control and Prevention (U.S.) ...

August 8, 2003 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)

:

A previously published report provided guidelines for managing the pharmacologic interactions that can result when patients receive protease inhibitor...

:

current
Initial Therapy for Tuberculosis in the Era of Multidrug Resistance; Recommendations of the Advisory Council for the Elimination of Tuberculosis

CITE Title : Initial Therapy for Tuberculosis in the Era of Multidrug Resistance; Recommendations of the Advisory Council for the Elimination of Tuberculosis Corporate Authors(s) : Advisory Council for the Elimination of Tuberculosis (U.S.);Center for Prevention Services (U.S.). Division of Tuberculosis Elimination.; Published Date : May 21, 1993 Pages in Document : print; i, 8 p. ; 22 cm. Series : Recommendations and Reports: Morbidity and Mortality Weekly Report (MMWR) Source : MMWR. Recommendations and Reports 1993; v. 42, no. 7 URL : https://stacks.cdc.gov/view/cdc/13595 Advisory Council for the Elimination of Tuberculosis (U.S.) (1993). Initial Therapy for Tuberculosis in the Era of Multidrug Resistance; Recommendations of the Advisory Council for the Elimination of Tuberculosis. 42(7). Advisory Council for the Elimination of Tuberculosis (U.S.) "Initial Therapy for Tuberculosis in the Era of Multidrug Resistance; Recommendations of the Advisory Council for the Elimination of Tuberculosis" 42, no. 7 (1993) Advisory Council for the Elimination of Tuberculosis (U.S.) "Initial Therapy for Tuberculosis in the Era of Multidrug Resistance; Recommendations of the Advisory Council for the Elimination of Tuberculosis" vol. 42, no. 7, 1993 Export RIS Citation Information.

:

Advisory Council for the Elimination of Tuberculosis (U.S.) ...

May 21, 1993 | Recommendations and Reports: Morbidity and Mortality Weekly Report (MMWR)

:

These recommendations update previous CDC/American Thoracic Society (ATS) recommendations for the treatment of tuberculosis (TB) among adults and chil...

:

superseded